NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price & News $1.04 +0.02 (+1.96%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$0.96▼$1.0450-Day Range$1.02▼$2.0152-Week Range$0.96▼$3.79Volume2.51 million shsAverage Volume1.45 million shsMarket Capitalization$254.73 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Lexicon Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside284.6% Upside$4.00 Price TargetShort InterestBearish7.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.31Based on 2 Articles This WeekInsider TradingAcquiring Shares$24,840 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.85) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.55 out of 5 starsMedical Sector899th out of 966 stocksPharmaceutical Preparations Industry411th out of 441 stocks 3.0 Analyst's Opinion Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Lexicon Pharmaceuticals has a forecasted upside of 284.6% from its current price of $1.04.Amount of Analyst CoverageLexicon Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.72% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXRX. Previous Next 2.0 News and Social Media Coverage News SentimentLexicon Pharmaceuticals has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lexicon Pharmaceuticals this week, compared to 1 article on an average week.Search Interest25 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows6 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,840.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.85) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lexicon Pharmaceuticals (NASDAQ:LXRX) StockLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Read More LXRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXRX Stock News HeadlinesOctober 2, 2023 | msn.comLooking Back In On Lexicon PharmaceuticalsSeptember 28, 2023 | finance.yahoo.comLexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023October 3, 2023 | UNKNOWN (Ad)Med-Tech Stock Set To Rally!With All The News That This Bio- Tech Stock Has had It Could Be Set To Rally!September 26, 2023 | finance.yahoo.comLexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)September 14, 2023 | finance.yahoo.comInsider Buying: Jeffrey Wade Acquires 10,000 Shares of Lexicon Pharmaceuticals Inc (LXRX)September 7, 2023 | finance.yahoo.comLexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)September 7, 2023 | finance.yahoo.comLexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment ConferenceAugust 28, 2023 | seekingalpha.comLexicon Pharmaceuticals Underway With Inpefa, But A Lot Of Hard WorkOctober 3, 2023 | UNKNOWN (Ad)Med-Tech Stock Set To Rally!With All The News That This Bio- Tech Stock Has had It Could Be Set To Rally!August 21, 2023 | finance.yahoo.comLexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023August 17, 2023 | finance.yahoo.com10 Healthcare Stocks with Insider BuyingAugust 8, 2023 | finance.yahoo.comPublished Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart FailureAugust 4, 2023 | finance.yahoo.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 49%, while individual investors hold 25%August 3, 2023 | finance.yahoo.comLexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 1, 2023 | finance.yahoo.comLXRX - Lexicon Pharmaceuticals, Inc.July 31, 2023 | benzinga.comLexicon Pharmaceuticals Board Member Awarded $191K Worth of Stock OptionsJuly 28, 2023 | finance.yahoo.comLexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023July 28, 2023 | finanznachrichten.deLexicon Pharmaceuticals, Inc.: Lexicon Elects Diane E. Sullivan to Board of DirectorsJuly 28, 2023 | finance.yahoo.comLexicon Elects Diane E. Sullivan to Board of DirectorsJuly 15, 2023 | seekingalpha.comLXRX Lexicon Pharmaceuticals, Inc.June 23, 2023 | finance.yahoo.comLexicon Announces Planned Advancement of LX9211 Into Late-Stage DevelopmentJune 21, 2023 | benzinga.comLexicon Pharmaceuticals And 2 Other Stocks Under $5 Insiders Are Aggressively BuyingJune 20, 2023 | finance.yahoo.comLexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific SessionsJune 15, 2023 | finance.yahoo.comUPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart FailureJune 10, 2023 | finance.yahoo.comLXRX Jan 2024 3.000 putJune 6, 2023 | finance.yahoo.comLexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare ConferenceJune 5, 2023 | finance.yahoo.comLexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional SharesSee More Headlines Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Company Calendar Last Earnings8/03/2023Today10/03/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CUSIP52887210 CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees135Year Founded1995Price Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+284.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,940,000.00 Net Margins-32,038.97% Pretax Margin-32,038.97% Return on Equity-97.63% Return on Assets-60.42% Debt Debt-to-Equity Ratio0.53 Current Ratio10.10 Quick Ratio10.09 Sales & Book Value Annual Sales$140,000.00 Price / Sales1,819.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book1.68Miscellaneous Outstanding Shares244,930,000Free Float228,270,000Market Cap$254.73 million OptionableOptionable Beta1.28 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Lonnel Coats (Age 58)CEO & Director Comp: $1.22MMr. Jeffrey L. Wade J.D. (Age 58)Pres & CFO Comp: $788.65kMr. Brian T. Crum (Age 49)Sr. VP, Gen. Counsel & Sec. Comp: $609.1kDr. Kenneth B. Kassler-Taub M.D. (Age 66)Sr. VP of Regulatory Affairs & Quality Assurance Comp: $588.7kDr. Craig B. Granowitz M.D. (Age 58)Ph.D., Sr. VP & Chief Medical Officer Comp: $671.14kDr. Robert J. Lefkowitz M.D. (Age 79)Consultant & Independent Director Comp: $50kMs. Kristen L. Alexander (Age 54)VP of Fin. & Accounting Carrie SiragusaExec. Director of Corp. Strategy and Investor RelationsChas SchultzExec. Director of Corp. Communications & Patient AdvocacyMs. Wendy E. McDermott (Age 52)VP of HR More ExecutivesKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDAVerastemNASDAQ:VSTMRigel PharmaceuticalsNASDAQ:RIGLMerrimack PharmaceuticalsNASDAQ:MACKEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsBaystate Wealth Management LLCBought 12,135 shares on 9/21/2023Ownership: 0.005%Jeffrey L WadeBought 10,000 shares on 9/14/2023Total: $13,800.00 ($1.38/share)Prosperity Financial Group Inc.Bought 26,000 shares on 9/12/2023Ownership: 0.011%Tucker Asset Management LLCBought 27,596 shares on 9/8/2023Ownership: 0.011%Wolverine Trading LLCBought 26,900 shares on 8/23/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions LXRX Stock - Frequently Asked Questions Should I buy or sell Lexicon Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares. View LXRX analyst ratings or view top-rated stocks. What is Lexicon Pharmaceuticals' stock price forecast for 2023? 1 Wall Street analysts have issued 12 month target prices for Lexicon Pharmaceuticals' shares. Their LXRX share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 284.6% from the stock's current price. View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts. How have LXRX shares performed in 2023? Lexicon Pharmaceuticals' stock was trading at $1.91 on January 1st, 2023. Since then, LXRX stock has decreased by 45.5% and is now trading at $1.04. View the best growth stocks for 2023 here. When is Lexicon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our LXRX earnings forecast. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.05. The biopharmaceutical company earned $0.32 million during the quarter, compared to analyst estimates of $0.30 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 97.63% and a negative net margin of 32,038.97%. What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO? 9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). What is Lexicon Pharmaceuticals' stock symbol? Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX." How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lexicon Pharmaceuticals' stock price today? One share of LXRX stock can currently be purchased for approximately $1.04. How much money does Lexicon Pharmaceuticals make? Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $254.73 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. How many employees does Lexicon Pharmaceuticals have? The company employs 135 workers across the globe. How can I contact Lexicon Pharmaceuticals? Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010. This page (NASDAQ:LXRX) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.